Tredje AP fonden Sells 39,000 Shares of Zoetis Inc. (NYSE:ZTS)

Tredje AP fonden lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 63.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,552 shares of the company’s stock after selling 39,000 shares during the quarter. Tredje AP fonden’s holdings in Zoetis were worth $3,674,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new stake in Zoetis in the third quarter valued at approximately $31,000. Dunhill Financial LLC increased its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Atlantic Edge Private Wealth Management LLC raised its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares during the last quarter. Finally, Quarry LP grew its position in Zoetis by 45.9% in the third quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after acquiring an additional 96 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Zoetis has an average rating of “Buy” and an average target price of $215.90.

Insider Transactions at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Trading Down 1.0 %

NYSE:ZTS opened at $160.03 on Friday. The firm has a market capitalization of $71.66 billion, a P/E ratio of 29.26, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a fifty day moving average of $166.86 and a 200 day moving average of $176.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.